- Ocuphire is positioning itself as a leading ophthalmic player, providing novel therapeutic solutions for both front and back of the eye indications.
- The company recently announced positive topline results for its lead candidate, Nyxol, in a Phase 3 study for Reversal of Mydriasis (RM) and in a Phase 2 study for Presbyopia.
- The company is targeting multi-billion dollar market opportunities in four indications, which remain largely unmet, and in some cases with no approved therapies or competition.
For further details see:
Ocuphire Pharma: An Undervalued Ophthalmic Play